Carlsmed, Inc.
CARLHealthcareNASDAQHealth Information Services · Last scanned Sep 8, 2026
Scan Results
Daily timeframeCarlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The $425.9M market capitalization puts CARL squarely in small-cap range for its industry. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures.
Market Cap
$425.9M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-11.30
EPS (TTM)
$-2.34
EPS (Fwd)
$-1.38
ROE
-66.1%
ROA
-28.2%
Cash
$89.2M
Total Debt
$21.9M
Free CF
-$26.4M
52W Change
16.0%
Annual Financials
Cash vs Debt
Where CARL stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, CARL finished 39.91% above its 150-day moving average ($11.70) and 35.40% above its 200-day moving average ($12.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CARL overbought or oversold?
At the September 2, 2026 close, CARL's RSI(14) was 71.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $89.2M in cash comfortably exceeding the $21.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$26.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -66.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $13.8M (2023) to $50.5M (2025), reflecting a 267% increase over the period.
With cash comfortably exceeding debt, CARL has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CARL.